USPTO Patent Application: Method for Forming Drops Dispersion

The USPTO has published a patent application detailing a method for forming a dispersion with fatty and aqueous phases, including specific steps for creating and conveying fatty phase drops. This application, filed by inventors Duncan Gilbert and Mathieu Goutayer, outlines a novel approach to dispersion formation for potential use in various product formulations.

USPTO Patent Application: RNA Complexes for Cancer Metastasis Treatment

The USPTO has published a new patent application detailing RNA complexes and nanostructures for cancer metastasis treatment. The application describes a one-step CMC production method for RNA therapeutic complexes containing nucleoside analogues, which self-assemble during RNA synthesis.

USPTO Patent Application: Inflammasome Inhibition for Neuroprotection

The USPTO has published a new patent application detailing methods for treating retinal detachment using inflammasome inhibition. The application, filed by Jayakrishna Ambati, Peirong Huang, and Kameshwari Ambati, focuses on improving visual outcomes for patients with rhegmatogenous retinal detachment.

USPTO Patent Application: Solid Dosage Form of Antiviral Nucleoside

The USPTO has published a new patent application from Merck Sharp & Dohme LLC for an oral dosage form of a small molecule antiviral nucleoside. The application details specific formulation components and pellet size requirements for the antiviral drug.

USPTO Patent Application: Neurodegenerative Disorder Treatment

The USPTO has published a new patent application (US20260083766A1) detailing methods for treating neurodegenerative disorders by modulating RNA editing. The application was filed on May 16, 2025, by inventors Nandkishore Raghav Belur and Joseph Robert Mazzulli.

USPTO Patent Application for NAD+ Concentration Support Compositions

The USPTO has published a patent application (US20260083765A1) for compositions and methods designed to support, optimize, and/or improve NAD+ concentrations in humans. The application details specific combinations of ingredients, including nicotinamide riboside, vitamins, and minerals.

USPTO Patent Application: Beta-1,3'-galactosyllactose for Gut Barrier Function Diseases

The USPTO has published a patent application (US20260083764A1) from N.V. Nutricia detailing the use of beta-1,3'-galactosyllactose for treating gut barrier function diseases, particularly in infants and young children. The application was filed on November 24, 2025.

USPTO Patent Application for Fiber-Based Prebiotic Dietary Supplements

The USPTO has published a patent application (US20260083763A1) for liquid compositions containing fiber as a prebiotic dietary supplement. The application details formulations designed to maintain or improve gut microbiome health.

USPTO Patent Application: Sialic Acid Compositions for Coronavirus Infections

The USPTO has published a patent application (US20260083762A1) detailing compositions comprising sialic acid for inhibiting or treating coronavirus infections, specifically those caused by SARS-CoV-2. The application was filed on August 18, 2025, by inventor Jan Remmereit.

USPTO Patent Application: Neuronal Migration Promoter for Brain Disease Treatment

The USPTO has published a patent application (US20260083761A1) from Public University Corporation Nagoya City University for a pharmaceutical composition and method to promote neuronal migration for treating brain diseases. The application details the use of a neuraminidase inhibitor.